SV

Street Verdict

Analyst Scorecard

A record of what Jefferies Analysis said publicly, with the source. Not advice.

Pending — not yet graded
“Jefferies recommends buying Torrent Pharmaceuticals, projecting a potential upside of 22-28% over the next 12 months. Despite expected challenges, the firm sees potential growth, with a target price ranging from ₹1,400 to ₹3,970.”

Jefferies Analysis’s track record (trackable calls only): 153 graded calls · 95% CI 37–53%

Torrent PharmaceuticalsBullishCalled 27 Jan 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Tracking Torrent Pharmaceuticals since this call

1-year tracking window
Read the original articleSee Jefferies Analysis’s full track record